Smoking prevalence remains high in some vulnerable groups, including those who misuse substances, have a mental illness, are homeless or are involved with the criminal justice system. E-cigarette use is increasing and may support smoking cessation/reduction.
A c c e p t e d M a n u s c r i p t cessation compared with placebo e-cigarettes and one RCT found no significant differences between e-cigarettes and nicotine patch (16) . However, overall evidence was considered of 'low' or 'very low' quality due to low event rates and wide confidence intervals. No serious adverse events were identified but long term safety data was lacking. Qualitative research in the general population suggests ecigarettes are able to attain to all the aspects of smoking considered important, being pleasurable, replacing habitual aspects and providing social connectedness (17) .
Estimated e-cigarette use prevalence among tobacco smokers in the United Kingdom (UK) is 21.9%, and 36.5% report 'ever use' (18) . In the USA 15.9% report current use and 47.6% ever use (19) . USA estimates suggest current use among smokers in community mental health treatment is 22% (20) and ever use among acute psychiatric admissions 11% and increasing (21) . Ever and current use among substance misusers are 73% and 33.8% respectively (22) . Past month e-cigarette use was estimated as 12-51% among homeless tobacco smokers (23) (24) (25) . No CJS data was available. Reasons for e-cigarette use include smoking cessation/reduction, (22) (23) (24) (25) (26) (27) (28) curiosity/experimentation, (22, 24, 28) use where smoking is banned, (23, 24, (26) (27) (28) lower cost (24) (25) (26) and harm reduction (24) (25) (26) (27) . E-cigarettes are regulated differently from smoking cessation therapies in many countries, and consequently funded differently, e.g. in the UK, unlike nicotine replacement therapy (NRT), bupropion and varenicline, e-cigarettes are not available on prescription and users must buy them. For vulnerable groups with potentially limited income, including the homeless, those in inpatient services and prison populations, cost may be a barrier. In view of the difference in funding mechanisms between e-cigarettes and other methods of smoking cessation support in many countries, health economics outcomes, such as economic impact of the adoption of e-cigarettes among vulnerable groups compared with other options for smoking cessation/reduction, are of interest.
In settings where smoking is banned e-cigarettes are often included without consideration of potential benefits. A c c e p t e d M a n u s c r i p t whilst a Public Health England (PHE) evidence update suggests smokers who have struggled to quit, or do not wish to, should be encouraged to switch to e-cigarettes as they are around 95% safer, but highlight that continued vigilance and further research is needed (30) . To date, there has been no systematic review of the effectiveness of e-cigarettes for vulnerable groups.
This report aims to (i) systematically review evidence for the effectiveness of ecigarettes for smoking cessation and reduction among these vulnerable groups; and (ii) identify barriers and facilitators to e-cigarette use.
The protocol was registered on PROSPERO (31) . Review questions were:
 Are e-cigarettes effective and cost-effective for smoking cessation or reduction for vulnerable groups?
 Are any adverse events associated with e-cigarette use in vulnerable groups?
 What are the barriers and facilitators to e-cigarette use for vulnerable groups?
METHODS
A systematic review of quantitative and qualitative literature on the effectiveness of e-cigarettes for smoking cessation and reduction among vulnerable groups, and barriers and facilitators to e-cigarette use, was conducted.
Inclusion criteria

Study design
A range of designs were included as scoping searches suggested limited available controlled evidence. The following study designs were eligible:
 For assessing effectiveness: randomised controlled trials (RCTs), cluster randomised controlled trials (cRCTs), quasi-RCTs, controlled before and after A c c e p t e d M a n u s c r i p t studies (CBA), interrupted time series (ITS), cohort studies, case-control studies and uncontrolled before and after studies (uBA).
 For assessing quantitative data on barriers and facilitators to e-cigarette use:
longitudinal, cross-sectional or cohort surveys.
 For assessing qualitative data on barriers and facilitators to e-cigarette use:
qualitative studies with any recognised method of data collection (e.g.
interviews, focus groups) and analysis from any discipline or theoretical tradition (e.g. grounded theory, thematic analysis).
Participants
Participants and carers' of any age in any country/setting in at least one of the following vulnerable groups: Those with transient psychiatric symptoms (e.g. self-reported depressive symptoms but no diagnosis/treatment for depressive disorder) were excluded as they were felt to face different challenges for smoking cessation e.g. time spent in a treatment facility and medication interactions. A c c e p t e d M a n u s c r i p t misuse, as they were thought to face different challenges for smoking cessation e.g. time spent in a treatment facility.
 Homeless: Individuals meeting national criteria for homelessness in the country/countries where the study was conducted or those accessing services for the homeless (35) . In the UK, legally a person is homeless if they have no accomodation they are entitled to occupy, or the accomodation they are entitled to occupy is in such poor condition they cannot be reasonably expected to occupy it (36). These four vulnerable groups, and not others, were chosen because they have particularly high smoking prevalence, suggesting smoking has not been denormalised among these groups, and because there is some overlap between the groups, for example prevalence of mental illness and/or substance misuse is high among the homeless (37) and people involved with the CJS (38).
Interventions
Studies investigating e-cigarettes, defined as 'electronic devices that heat a liquid into an aerosol for inhalation. The liquid usually comprises propylene glycol and glycerol, with or without nicotine and flavours, and stored in disposable or refillable cartridges or a reservoir' (16) . Disposable, non-rechargeable e-cigarettes, rechargeable e-cigarettes with replaceable pre-filled cartridges, and rechargeable ecigarettes with a refillable tank reservoir into which 'e-liquid' is added were included (39). 'Heat not burn' products, in which heated tobacco is vaporised, were excluded (40).
Comparison group
 E-cigarette versus another type of nicotine or non-nicotine e-cigarette;  E-cigarette versus no or delayed intervention.
Uncontrolled before and after studies were included if baseline measurements were reported. Weaknesses of such designs are considered in quality assessment below.
Outcome measures
Studies reporting on any of the primary or secondary outcomes were included.  Serious or non-serious adverse events. Adverse event was defined as 'any undesirable experience' associated with use (42) . It was considered serious if it led to death, threatened life, hospitalisation (initial or prolonged), permanent damage/disability, congenital anomaly, required intervention to prevent permanent impairment/damage, or other important medical events which may jeopardise the patient and/or require medical/surgical intervention. Of particular interest were interactions with prescribed psychiatric medications, fires caused by e-cigarette chargers or self-harm associated with e-liquid.
 Perceived barriers and facilitators to e-cigarette use. 
Database searches
Following searches from similar systematic reviews (15, 16, 35) a strategy was developed in MEDLINE using MeSH and free text terms (Box 1), tested against a sample of relevant papers and adapted for other databases.
Searches were from 2004, when modern e-cigarettes became available (16) to March 2017. Reference lists of included studies and systematic reviews were screened. Searches were not restricted by language but studies without a full text available in English would have been excluded, although none relevant were identified. Articles not referring to any included vulnerable group(s) or to e-cigarettes by any recognisable name, in the title/abstract, were excluded.
Data extraction
Search results were merged using Endnote and de-duplicated. Titles and abstracts were screened according to pre-specified inclusion/exclusion criteria by one author (SG) with 10% double screened by a second (CN). There were two discrepancies, which were resolved by discussion. Potentially included full text articles were retrieved and reviewed and 10% double screened, with no discrepancies. Data were extracted using a standardised data extraction sheet by SG and a sample (four studies) double checked by CN, with no discrepancies. Double screening and data extraction of only a sample was necessary due to resource limitations, and has been done in similar reviews (15, 43, 44) . To explore relationships in the data, themes emerging from qualitative data were mapped onto the COM-B model, a 'behaviour system' within which capability, motivation and opportunity interact to generate behaviour, which also influences each of these components (54) . Capability includes both practical and psychological components, motivation includes automatic and reflective processes, and opportunity includes physical aspects, such as physical accessibility, and social aspects, such as community or family support. The model has been applied to tobacco control (54) and general population e-cigarette use (55) but not as part of a systematic review on e-cigarette use among vulnerable groups. Application of the COM-B model was considered appropriate for this systematic review because relating data to the conditions which this established theory assumes must be met for behaviour to change, which are likely different for vulnerable groups compared 
RESULTS
The PRISMA Flow Diagram (56) reports records identified, duplicates, records screened and included/excluded, full text articles assessed and studies included in narrative synthesis ( Figure 1 ).
Study characteristics
Searches revealed 9 studies meeting the inclusion criteria. Five quantitative studies were included (total participants n=1089). Of the included quantitative interventional studies (total participants n=133), there was one secondary analysis (57) of an RCT (58) , and three uncontrolled before and after studies (6, 59-61) (one study was reported in both a conference abstract (61) and a full article (59)). One cohort observational study was included (n=956) (21) . Four qualitative studies were included (62-65); three involving focus groups (n=128) (63-65) and one qualitative analysis of online postings (62) . Five studies were performed in the USA (6, 21, 60, 63, 64) and one in each of Australia (65), Italy (59, 61), New Zealand (57) and international posters online (62) .
Participants
Six studies included participants with mental illness (6, 21, 57, 59, 61, 62, 65) , two homelessness (63, 64) , and one substance misusers (60) . No studies involving the CJS were identified. Attrition was minimal.
M a n u s c r i p t
Mental illness populations were heterogeneous and included people reporting being prescribed one or more psychiatric medications (57) , SMI diagnosis (6), schizophrenia (59, 61) and acute psychiatric admissions (21) . Self-report psychiatric medication use is likely less accurate for case ascertainment than ICD-10/DSM-IV criteria. Qualitative studies included community mental health clients (65) and posters discussing e-cigarettes in the context of mental illness online (62) .
Two qualitative and no quantitative studies involving homeless populations were identified. One recruited from homeless shelters (63) . The second included homeless parents living in family shelters (64) .
Only one quantitative study (60) and no qualitative studies focussed on substance misusers. The study involved people on methadone and may not be representative of users of other substances. Number of participants included in each study are reported in Table 1 . Participant characteristics of quantitative and qualitative studies are detailed in Supplementary Tables 1 and 2 respectively.
Interventions and comparisons
Four intervention studies were identified (6, 57, 59, 60) . The main intervention focus was free provision of e-cigarettes, suggesting researchers may have considered cost a barrier. Only one study included behavioural support (low intensity voluntary telephone counselling) (57). One study offered e-cigarette use instructions plus telephone technical and medical assistance (59) . The remaining studies provided only instructions for use (6, 60) . No explicit theoretical basis for interventions were described. One study emphasised collecting 'real-life' data hence no encouragement or motivational support was provided (59) . All suggested e-cigarettes may be considered a harm reduction strategy (6, 57, 59, 60) . See Supplementary Table 3 for further intervention details.
M a n u s c r i p t
Five studies addressed smoking cessation (6, 21, 57, 59, 60) , four adverse events (6, 57, 59, 60) , five smoking reduction (6, 21, 57, 59, 60) and four reported qualitative data on barriers and facilitators to e-cigarette use (62) (63) (64) (65) .
Quality assessment
Four of the included quantitative studies were rated globally as weak (6, 21, 59, 60) using the EPHPP criteria (46) , and one was rated moderate (57) . Included qualitative studies were of moderate quality, with global scores calculated based on the CASP checklist ranging from 6-8 out of ten. Further details on the scores for each criteria are available in Supplementary Tables 4 and 5 .
Primary outcomes
Smoking cessation
Four interventional studies assessed smoking cessation outcomes among those receiving an e-cigarette intervention (6, 57, 59, 60) . Smoking cessation varied from 0.0% (60) -14.3% (59) (details of how each study defined smoking cessation are provided in Table 1 ). Three studies included people with mental illness (6, 57, 59) and one, people on methadone (60) . Three studies were rated as weak on quality appraisal and included fewer than 30 participants, making statistical analyses potentially unreliable (6, 59, 60) . The fourth was rated moderate and was the only study with a control group (57) . There were no significant differences between One observational study involving people with mental illness found no significant difference between e-cigarette users and non-users (21) ( Table 1 ). Participants were part of an RCT comparing brief, extended and usual smoking cessation treatment, so may not be representative of wider mental illness populations.
Adverse events
No serious adverse events were reported (6, 57, 59, 60) . Some side effects were Supplementary Table 6 .
Barriers and facilitators
Four moderate quality qualitative studies reporting data relating to these outcomes (62) (63) (64) (65) were thematically synthesised and mapped to the COM-B model (Figure 2 ).
How qualitative data link to each aspect of the framework is discussed below, with barriers and then facilitators presented, with illustrative quotes. Supplementary Table   7 details which themes arose from which studies.
A c c e p t e d M a n u s c r i p t
Physical capability
Physically accessing, safely operating and maintaining supplies to use an e-cigarette was a barrier (62, 65) :
"I think you would have to be organised and organise your finances and make sure that when it does run out you've got something to fill it up with, because that would be the time when you go, "Oh bugger I've run out of this" and you would go and buy a packet of cigarettes or whatever." (65) Concerns were raised about safely refilling, charging, and cleaning. Potential danger of 'e-liquid' for those at risk of self-harm was concerning (62, 63, 65) :
"I think what the OP [original poster] means is that nicotine on its own is more poisonous than cyanide and arsenic. 60 mg will kill a light smoker, and I believe 45 mg is enough to kill many people who don't smoke. Giving nicotine juice to someone with major depressive disorder may not be the best idea in the world." (62) Assistance from family/carers and design (e.g. closed cartridges) were suggested solutions (62):
"My mother has schizophrenia . . . She has a terrible smokers cough and I think if I could get her to swap to e-cigarettes it would make a hell of a difference . . . Trouble is it needs to be dead simple. Even the recharging could cause problems and the refilling almost certainly would have to be done periodically by members of the family . . . Good charge and easy to charge.
Maybe affordable enough to have a few so she can wait for a family member to refill or very easy to refill." (62) Psychological capability E-cigarettes were considered less harmful than cigarettes and were an alternative source of nicotine for cessation (62) (63) (64) (65) and reduction (62, 63, 65) :
"I quit through vaping, not just a little tiny one but it's good to invest on something expensive. Although you're trading one addiction for another, it's A c c e p t e d M a n u s c r i p t the lesser of the two evils. I was a pack a day smoker and I quit within two weeks." (62) "yeah an e-cigarette really helped me to quit smoking. Like even when I was pregnant and trying to quit smoking I used a patch, like the doctors prescribed me a patch to quit smoking and that didn't even work as well as the ecigarette did." (63) Physical opportunity Some spent more money personalising e-cigarette/vaping equipment than they previously did on cigarettes, whilst others found them cheaper (62, 65) . Balancing personalisation with affordability was considered necessary: A c c e p t e d M a n u s c r i p t cigarette]…I was like oh my god, they're allowing smoking on TV because you don't really see that too often. I don't remember seeing a commercial promoting smoking, so it was like advertising directed to me, but the whole Newport thing, that was a whole culture, you know like this is what you do, you're cool, you're high, you're drinking and by the way, have a Newport." (63) Family/friends, healthcare professionals and online posters facilitated e-cigarette initiation and provided moral and practical support. E-cigarettes were socially acceptable and provided a community of 'vapers' with opportunities for interaction and connectedness (62): "I went through it faster than I probably would have a pack of cigarettes and then also my brother enlightened me, he was like e-cigarettes they say they're supposed to be better for you because it's vapor this and that, but really it's not because it gives you the opportunity to smoke cigarettes in places where you can't smoke. So you're smoking that and you're in an environment where it's not smoking, but the e-cigarette is allowed, but technically yeah you're not harming anybody else, but you're still smoking...you're still harming yourself, so you're smoking more than you normally would smoke." (63) E-cigarettes were perceived to have both beneficial and negative effects on psychiatric symptoms and medication side effects (62, 65) :
"I have PTSD, anxiety symptoms from that, and TBI-related memory issues and micro seizures. For me, vaping is pretty much the same as smoking, in terms of how it helps me calm down and handle stress." (62) "Vaping doesn't really do it for me. That's due to there being chemicals in burnt tobacco that function very similar to antidepressants (which is one of the big things that makes tobacco addicting). vaping doesn't have those, and thus only has the effects of nicotine, which aren't as strong." (62) E-cigarettes were more desirable than NRT (62) (63) (64) (65) :
"Of the cessation tools discussed, participants were much more interested in e-cigarettes or replacing smoking with an alternative habit than they were in using either patches or medication.." (64) 
[Author interpretation]
Ability to take charge of nicotine addiction was empowering (62), facilitated by ability to choose and personalise the device (62, 65) : 
Secondary outcomes
Smoking reduction
Five studies reported on smoking reduction (6, 21, 57, 59, 60) . A moderate quality study of people on medication for mental illness suggested a reduction of 9.9 cigarettes/day among 16mg nicotine e-cigarette users compared with 5.7 among patch users (Table 2) (57). This difference was statistically significant and, if sustained, may lead to clinically significant differences, but the study lasted only 26 weeks and included only 86 participants. There was some evidence from three weak quality uncontrolled before and after studies of statistically significant smoking reduction from baseline to follow up for participants with mental illness (6, 59) and M a n u s c r i p t substance misuse (60) . Reduction was confirmed with eCO among those with mental illness. However, as there was no control group, it is unclear if these reductions would have occurred without e-cigarettes. An observational study found no significant reduction in smoking among e-cigarette users (21) .
Other treatment and health economics outcomes
No studies reported on treatment retention or health economics.
DISCUSSION
The primary objective of this systematic review was to assess effectiveness of ecigarettes for smoking cessation among vulnerable groups. Due to low quality of available evidence, whether e-cigarettes are effective remains uncertain. There was some evidence from a moderate quality study that e-cigarettes were as effective as NRT for smoking cessation. There was some evidence from four studies of statistically and clinically significant smoking reduction, however, three were uncontrolled and had sample sizes less than 30. There were no differences between e-cigarette users and non-users in a prospective cohort study, although there were limitations in case ascertainment (participants asked about "all forms of tobacco use") and as participants were recruited from an RCT of smoking cessation interventions, those who had already stopped/reduced smoking using e-cigarettes may not have participated (16) .
Villanti et al. propose methodological criteria for determining whether a study provides sufficient information to establish whether e-cigarettes facilitate smoking M a n u s c r i p t cessation/reduction: 1) examines outcome of interest; 2) assesses e-cigarette use for cessation as exposure of interest; 3) employs appropriate control/comparison; 4) ensures measurement of exposure preceded outcome; 5) evaluates dose and exposure duration; and 6) evaluates type and quality of device (66) . All the included quantitative studies assessed cigarette abstinence. Only two studies assessed ecigarette use for cessation as the exposure of interest (57, 60) . Only one study included an appropriate control group (57) . The four interventional studies ensured exposure preceded outcome (6, 57, 59, 60) . None evaluated dose, exposure week complete self-reported and CO verified abstinence (not even a puff) for 30 days before assessment (59) .
Qualitative thematic synthesis revealed barriers and facilitators mapping to each component of the COM-B model, and suggests e-cigarettes have the potential to be able to attain to key aspects of smoking addiction, being pleasurable, replacing habitual aspects, providing an alternative identity as a 'vaper' and facilitating social connectedness through a vaping community. It also suggests vulnerable groups may require additional support to enable e-cigarette use, in terms of choosing a device, using it safely, access to e-cigarettes and accessing the social connectedness 'vaping' can provide.
No serious adverse events were reported. Qualitative studies highlighted concerns about e-liquid access for those at risk of self-harm, which case reports show has been used in intentional overdose (67) . Future studies should consider how design adaptations could improve safety. 
Strengths and limitations of the evidence base
Three of the five included quantitative studies had sample sizes of less than 30.
Some studies included only self-report smoking reduction, risking recall bias. Neither the uncontrolled before and after studies nor the cohort study adjusted for confounders. Failure to adjust for confounders, including level of nicotine dependence, in cohort studies of NRT led to underestimation of effectiveness (16, 69) .
Overall quantitative evidence was weak. Qualitative evidence was moderate. Much available qualitative data was from a single study analysing online posts about ecigarettes for those with mental illness. Those who are motivated to post online are more likely to have strong views, reducing transferability. However, such methods obtained rich data from participants using a self-initiated innovative nicotine delivery device.
Heterogeneity of included studies in terms of participants, interventions, comparisons and outcomes reduced comparability and prohibited meta-analysis. All included studies were from high income countries, thus generalisability to other settings is limited, and publication bias is a possibility.
No data were found on the CJS. E-cigarettes are a consumer product that entered and have proliferated in the market largely outside the health arena, in contrast to medicinally licensed products (e.g. NRT) (17) . This may be why little data is available for the CJS, where access to such consumer products is restricted. As more prisons become smoke-free, with some recognising the potential role of e-cigarettes in supporting smoking abstinence, this evidence gap may begin to be filled. None of the included studies discussed 'vaping' other substances (e.g. cannabis), which may be of concern (30), particularly among substance misusers.
Strengths and limitations of this review
Strengths include the comprehensive search strategy, triangulation of quantitative and qualitative data, application of behaviour change theory and focus on underserved populations.
The scope of this review specified four vulnerable groups (people with mental illness, substance misuse, homelessness or CJS involvement), but other groups may also be considered vulnerable, including young people, pregnant women, lower socioeconomic groups and indigenous populations (35) , and the effect of ecigarettes on these groups should be considered in future studies.
That it was only feasible to independently double screen 10% of citations is a limitation. Richness of qualitative synthesis was restricted by the limitations of available data. Triangulation of qualitative and quantitative data and application of the qualitative data to a recognised theory of behaviour change has attempted to make the most of extremely limited available data.
Implications
This review highlights the need for further research into the role of e-cigarettes for vulnerable groups and the challenge of making recommendations for public health policy.
The available evidence assessing effectiveness of e-cigarettes for smoking cessation for vulnerable groups was limited. No serious adverse events were identified, and side effects were minimal. In view of the harm caused by tobacco, recommendations from PHE that e-cigarettes be considered for those who have M a n u s c r i p t been unable to stop smoking (30) appears appropriate for vulnerable groups as well as the general population.
Qualitative data highlighted concerns about e-cigarettes reversing de-normalisation of smoking (63) . However, tobacco is arguably yet to be de-normalised among these groups (35) . Consideration of the differences in harm between e-cigarettes and tobacco is needed before including the former in smoking bans. PHE report negligible levels of nicotine in ambient air and no health risks for bystanders have been identified (30) . The South London and Maudsley NHS Foundation Trust, an English mental health trust, implemented a 'smoke-free' policy including guidance supporting e-cigarette use in bedrooms and grounds for patients who have tried other cessation methods (70) .
No cost-effectiveness studies were identified. Unlike NRT, e-cigarettes are unlicensed and not available on prescription, thus users pay for them (30) . 'Starter kits' including battery, charger and replaceable nicotine cartridges cost £17-90 (71).
Future directions
Pilot studies comparing different intervention designs for usability and safety for vulnerable groups would be beneficial. Adequately powered RCTs comparing e- M a n u s c r i p t Week 5
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